Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Tiny blood particles may hold early clues to type 2 diabetes risk in obesity

NCT ID NCT07728591

Diagnosis Sponsor: Hong Kong Baptist University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 27, 2026 · Last updated Jul 31, 2026 · Updated 3 times

Summary

This study investigates whether specific proteins found in tiny particles in the blood (called small extracellular vesicles) can help identify obese individuals who are at risk for developing type 2 diabetes. Researchers will measure levels of two proteins, integrin-β2 and ECM1, in blood samples from 120 adults aged 40–59 who are either normal weight, overweight, or have prediabetes or type 2 diabetes. The goal is to see if these proteins can serve as early warning signs, allowing for earlier intervention to prevent or delay diabetes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a simple blood test that identifies obese individuals at high risk for type 2 diabetes before the disease develops.
What could go wrong
This is an early, small study measuring protein levels, not a proven screening tool. The findings may not translate into a reliable test for broader populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will consist of Hong Kong residents aged 40 to 59 years recruited from the Hong Kong Baptist University Mr. \& Mrs. Chan Hon Yin Chinese Medicine Specialty Clinic and Good Clinical Practice Centre, as well as through recruitment posters and social media announcements. Participants will be classified into four groups according to BMI and glycemic status: non-overweight/non-obese participants without prediabetes or type 2 diabetes, overweight/obese participants without prediabetes or type 2 diabetes, non-overweight/non-obese participants with prediabetes or type 2 diabetes, and overweight/obese participants with prediabetes or type 2 diabetes. Approximately 30 participants will be enrolled in each group.

Ages

40 to 59 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Hong Kong citizens; * Male or female; * Aged 40-59 years; * Able and willing to provide written informed consent; * Willing to undergo BMI assessment and fasting blood collection after an overnight fast of at least 8 hours. Exclusion Criteria: * Cardiovascular disease. * Cancer. * History of surgery, as specified in the study protocol. * Infectious disease. * Osteoarthritis. * Genetic disease. * Pregnancy or breastfeeding. * Suspected pregnancy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity / overweight are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight prediabetes syndrome type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity / overweight Prediabetes / type 2 diabetes

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites in 2 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hong Kong Baptist University Mr. & Mrs. Chan Hon Yin Chinese Medicine Specialty Clinic and Good Clinical Practice Centre

    Kowloon Tong, Hong Kong

  • The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University

    Luzhou, Sichuan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.